Our study portfolio

STRIKE-001: Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer

PSMA-007-001: A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

TALENT: TALazoparib with or without ENzaluTamide in patients with metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate

TIDAL: Phase 2 Study of Tarlatamab in Patients With Delta-like Protein 3 (DLL3) Positive Metastatic Prostate Cancer

TIP: A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer

MOMENT: A Phase 2, Open-label, Single-Arm Study of Mevrometostat Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Following Prior Androgen Receptor Pathway Inhibitor Therapy

LuX: A Feasibility Study of Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

PRESERVE-006: Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer

DORA: A Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer

NivoDoce: A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors

SAABR: Single Arm Phase II Study of AR Targeted Therapy + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

MetaCure: Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Ribo-X: Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

IRRADIANT: IRreversible Electroporation versus RADIAtioN BoosT for Intermediate Risk Prostate Cancer

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With mCRPC

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPi or Docetaxel in Patients with mCRPC

AB-3028, a Programmable Circuit T Cell Therapy in Patients with CRPC

A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination with Darolutamide in mCRPC

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients with Progressive mCRPC

SEACLIFF: A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Metastatic Prostate Cancer

A Phase 1b Study of 177Lu-PSMA-617 Combined with Liver Directed Therapy in mCRPC

A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination with Androgen Receptor Pathway Inhibitors in Participants with mHSPC

A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer

A Study of FG-3246 in Participants With mCRPC

Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with mCRPC

Phase 1/2 Study of HLD-0915 in Patients with mCRPC

A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in Combination with Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With mCRPC

A Phase 1a/b Study of ADRX-0405 in Subjects with mCRPC and Select Advanced Solid Tumors

PHAROS: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer

Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients with Metastatic Prostate Cancer

CONVERGE-01: A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive CRPC

Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination with a PARP Inhibitor in Participants with Advanced or Metastatic Solid Tumors

LEGION-100: A Phase 1b Open-Label, Dose-Escalation Study of SYNC-T Therapy SV-102 in Patients Diagnosed with mCRPC

RADIODOSE: A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults with mCRPC: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE)

A Phase 2 Study of Biomarker-Modulated PSMA Theranostics: Low PSMA SUV Boost (LPS-Boost) – Intensified 177Lu-PSMA-617 Treatment for Patients with mCRPC with Low PSMA Expressing Disease

DIVINE: Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent HSPC

MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With mCRPC

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant mCRPC

A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination with Darolutamide in mCRPC

Developing and Testing a Patient-Centered Tumor Genomic Pre-Test Counseling Tool for African-American men with Metastatic Prostate Cancer

METANOVA: Metastasis-directed radiotherapy (MDRT) for men with de-novo oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial

A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined with JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

A Phase 1, Open-label Study of BMS-986460 in Participants with mCRPC

Internet-Based Lifestyle Intervention (iLIVE) to Eradicate Obese Frailty in Prostate Cancer Survivors

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients with High-Risk Localized Prostate Cancer

A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation

The SKYBRIDGE study, an Open-label, Multicenter, Dose Escalation and Dose Expansion Phase 1/2 Study with PT217 Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients with NeuRoendocrIne Carcinomas That Are Known to Be DLL3 ExpressinG CancErs

SNARE: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination with AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer with PTEN Loss

A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients with Targeted Advanced Solid Tumors and Hematological Malignancies

A Phase 2 Randomized Study of Abiraterone Acetate, Enzalutamide or Apalutamide as First Line Therapy in Veterans with CSPC

An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients with Metastatic Prostate Cancer

TERPS: Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial

VA Bipolar Androgen Therapy (VA-BAT Trial): High-dose Testosterone in Men with mCRPC and ATM, CDK12, or CHEK2 deficiency

Randomized Phase 2b Study of ZEN003694 in Combination with Enzalutamide versus Enzalutamide Monotherapy in Patients with mCRPC

Phase I/II Trial of Pembrolizumab and Androgen-Receptor Pathway Inhibitor with or without 225Ac-J591 for Progressive mCRPC

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing mCRPC [SECuRE (Systematic Cu Theranostics in Prostate Cancer)]

GUNS: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

The STEP-UP Trial: Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide alone in Asymptomatic Men with mCRPC

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With mCRPC

COBRA: Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) with Cemiplimab (Anti-PD-1) in Patients with mCRPC and Other Tumors Associated with PSMA Expression

A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)